Genesis Technology Group, Inc. announced today the signing of a letter of intent with BersaChem, Inc., a US-based healthcare company that has developed and holds a US-patented proprietary formula for X-Teril, a high level disinfectant solution.

Genesis has secured a 3-month renewable exclusive to source a manufacturing and distribution partner in China. Upon securing an acceptable joint venture partner, Genesis could seek a long-term contract for exclusive manufacturing and marketing rights in China.

Mr. Bernardo Birnbaum, BersaChem president, commented: "In considering a marketing strategy for China, we were impressed by Genesis' history and ability to effectively transfer technologies. X-Teril is ideally suited for Chinese hospitals and institutions. X-Teril, a patented disinfectant that has met all compliance requirements from the Venezuelan Ministry of Health, could combat avian flu, SARS and other airborne diseases in China. We have contracted with Genesis to introduce this important product line to the world's most dynamic market."